Science
Moderate to Severe
Traumatic Brain Injury.
PresSura is targeting the control of intracranial pressure (ICP) to prevent injury caused by brain swelling. All preclinical and Phase 1 development has been completed and an international Phase 2A programme has completed patient enrolment. Success is expected to result in a paradigm shift in the treatment of elevated ICP.
Moderate to Severe
Traumatic Brain Injury.
PresSura is targeting the control of intracranial pressure (ICP) to prevent injury caused by brain swelling. All preclinical and Phase 1 development has been completed and an international Phase 2A programme has completed patient enrolment. Success is expected to result in a paradigm shift in the treatment of elevated ICP.
Targeted Benefits.
A successful treatment would deliver significant improvements in functional independence and quality of life, helping people regain control over daily activities, cognitive function and physical abilities. By reducing the health burden of TBI, it would also lower the economic burden of ongoing medical support, therapies, neurological medications, compensating strategies and community reintegration.
Targeted Benefits.
A successful treatment would deliver significant improvements in functional independence and quality of life, helping people regain control over daily activities, cognitive function and physical abilities. By reducing the health burden of TBI, it would also lower the economic burden of ongoing medical support, therapies, neurological medications, compensating strategies and community reintegration.
Mode of Action.
A traumatic brain injury triggers a vicious cycle of neurogenic inflammation, oedema and classical inflammation. EU-C-001 is designed to interrupt this cycle, allowing the brain to recover by stopping the process of oedema formation.
Corrigan et al., 2016
Proteins released as a consequence of brain injury.
Trigger development of neurogenic inflammation and oedema.
Leading to “Classical Inflammation” releasing histamine
Histamine triggers further protein release and a vicious cycle
Corrigan et al., 2016